Korro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm Holding

KRRO-110 miss drives overhaul; KRRO-121/111 show preclinical promise. Click here to read my most recent analysis of the stock ...
Nasdaq

Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

Shares of Altimmune ALT fell 27.04% during market hours on Sep 14, even after the company announced positive top-line results from its 12-week phase I study. The study evaluated pemvidutide in ...

Why Promising Lab Drugs Fail: Study Finds How Body Environment Can Flip Drug Effects

Findings published in the journal Nature Structural and Molecular Biology could help explain why drug candidates can look ...
Nasdaq

Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints

Biohaven Pharmaceuticals BHVN recently announced that the phase II/III HEALY ALS platform study evaluating verdiperstat for treating Amyotrophic Lateral Sclerosis (ALS) failed. ALS is a progressive, ...